Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FSD Pharma Inc. - Class B Subordinate Voting Shares (NQ:HUGE)

0.0899 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about FSD Pharma Inc. - Class B Subordinate Voting Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
FSD Pharma Inc. Board Approves Share Repurchase Program ↗
FSD Pharma (NASDAQ: HUGE), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is repurchasing up to 2 million company shares. The... 
Via Benzinga
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program
Via Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program
Via Investor Brand Network
News headline image
FSD Pharma Announces Share Repurchase Program
From FSD Pharma Inc.
Via Business Wire
News headline image
Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S. ↗
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
News headline image
FSD Pharma Announces Establishment of Advisory Board, Strategic Appointments ↗
FSD Pharma (NASDAQ: HUGE), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has formed a regulatory... 
Via Benzinga
News headline image
FSD Pharma Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating ↗
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data... 
Via Benzinga
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating MS
Via Investor Brand Network
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Announces Establishment of Advisory Board, Strategic Appointments
Via Investor Brand Network
News headline image
FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish
From FSD Pharma Inc.
Via Business Wire
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been... 
Via FinancialNewsMedia
News headline image
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition
From FSD Pharma Inc.
Via Business Wire
News headline image
Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold ↗
Contents 
Via Benzinga
News headline image
Nasdaq-listed FSD Pharma To Advance Psychedelics Pipeline With $9 Million Acquisition Of Lucid Psycheceuticals ↗
FSD Pharma Inc. (NASDAQ:HUGE) (CSE: 
Via Benzinga
News headline image
FSD Pharma To Buy Canadian Psychedelic Pharmaceutical Firm ↗
FSD Pharma Inc (NASDAQ: HUGE) shares rebounded after falling in premarket on acquiring a Canada-based psychedelic pharmaceutical company. Related: See Why FSD Pharma... 
Via Benzinga
News headline image
54 Biggest Movers From Yesterday ↗
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining over 11% on Tuesday. Regencell Bioscience recently... 
Via Benzinga
News headline image
36 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Locust Walk Acquisition Corp. (NASDAQ: LWAC) shares jumped 188% to $25.34 after the company announced stockholders approved a business combination with eFFECTOR... 
Via Benzinga
News headline image
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals
From FSD Pharma Inc.
Via Business Wire
News headline image
See Why FSD Pharma Terminated COVID-19 Trial ↗
FSD Pharma Inc (NASDAQ: HUGE) will terminate the Phase 2 trial of ultra-micronized palmitoylethanolamide (PEA), or FSD-201, for COVID-19. FSD-201 works by... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug ↗
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
News headline image
21 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) rose 40.1% to $21.43 in pre-market trading after gaining over 11% on Tuesday. Regencell Bioscience recently reported... 
Via Benzinga
News headline image
FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial
From FSD Pharma Inc.
Via Business Wire
News headline image
FSD Pharma Inc. Announces Termination of Chief Executive Officer Dr. Raza Bokhari for Cause
From FSD Pharma Inc.
Via Business Wire
News headline image
64 Biggest Movers From Friday ↗
Gainers Senseonics Holdings, Inc. (NYSE: SENS) jumped 42% to settle at $2.91 on Friday after the company disclosed results from a PROMISE study evaluating its Eversense CGM... 
Via Benzinga
News headline image
40 Stocks Moving In Friday's Mid-Day Session ↗
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares jumped 68.8% to $25.49 after gaining 23% on Thursday. Senseonics Holdings, Inc. (NYSE: SENS) gained 26% to $2.5817 after the... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.